Granted Patent
B2
US 12,459,896 · App. 18/988,131 · Granted Nov 4, 2025
Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
Inventors:
Austin Gerald Smith (Cary, NC); Padmini Kavuru Ananthoji (Townsend, MA); Peter Dornan (Stoneham, MA); Xijie Dai (Winchester, MA)
Assignee:
AMGEN INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are processes for preparing Compound A or a salt thereof, comprising admixing Compound B or a salt thereof and crotonaldehyde in the presence of an acid catalyst and a solvent to form Compound A
Claims (26)
1 . A process for preparing Compound A or a salt thereof
comprising:
admixing Compound B
or a salt thereof, and crotonaldehyde in a solvent and in the presence of a catalytic reagent;
wherein the catalytic reagent comprises an acid catalyst, an organocatalyst, or a combination thereof.
2 . The process of claim 1 , wherein the acid catalyst comprises a Bronsted-Lowry acid.
3 . The process of claim 1 , wherein the acid catalyst comprises a Lewis acid.
4 . The process of claim 3 , wherein the Lewis acid comprises a metal halide, a triflate, a boron etherate, or a combination thereof.
5 . The process of claim 4 , wherein the metal halide is selected from the group consisting of AlCl 3 , CuCl 2 , FeCl 3 , ZnBr 2 , and a combination thereof.
6 . The process of claim 4 , wherein the triflate is selected from the group consisting of a metal triflate, a silyl triflate, and a combination thereof.
7 . The process of claim 4 , wherein the metal triflate is selected from the group consisting of Al(OTf) 3 , Bi(OTf) 3 , Cu(OTf) 2 , Sc(OTf) 3 , In(OTf) 3 , La(OTf) 3 , Yb(OTf) 3 , Zn(OTf) 2 , and a combination thereof.
8 . The process of claim 1 , wherein the organocatalyst comprises an amine and wherein the amine comprises a secondary amine or a salt thereof.
9 . The process of claim 1 , wherein the organocatalyst comprises pyrrolidine or a salt thereof.
10 . The process of claim 1 , wherein the solvent comprises a polar aprotic solvent.
11 . The process of claim 1 , wherein the solvent is selected from the group consisting of water, methanol, ethanol, isopropanol, acetic acid, acetonitrile, acetone, cyclopentyl methyl ether, ethyl acetate, methyl isobutyl ketone, isopropyl acetate, tetrahydrofuran, methyl tert-butyl ether, N-methylpyrrolidone, dimethylsulfoxide, dimethylformamide, toluene, n-heptane, and a combination thereof.
12 . The process of claim 1 , wherein the solvent comprises acetonitrile.
13 . The process of claim 1 , wherein Compound A is substantially free of
14 . The process of claim 9 , further comprising admixing pyrrolidine and hydrochloric acid in a second solvent to form pyrrolidine hydrochloride.
15 . The process of claim 1 , further comprising heating Compound A or a salt thereof to a temperature of at least 30° C. in the presence of an acid or a base to form Compound F or a salt thereof
16 . The process of claim 15 , wherein Compound A or a salt thereof is heated to a temperature of 65° C. to 110° C.
17 . The process of claim 15 , wherein the acid is selected from the group consisting of sulfuric acid, hydrochloric acid, phosphoric acid, and a combination thereof.
18 . The process of claim 15 , wherein the base comprises a metal hydroxide.
19 . The process of claim 15 , further comprising admixing Compound F with an oxidizing agent and a base to form Compound G:
20 . The process of claim 19 , wherein the oxidizing agent is selected from the group consisting of sodium hypochlorite, sodium hypobromide, N-bromosuccinimide, lead tetraacetate, and a combination thereof.
21 . The process of claim 20 , wherein the base is selected from the group consisting of sodium hydroxide, potassium hydroxide, 1,8-diazabicyclo[5.4.0]undec-7-ene, and a combination thereof.
22 . The process of claim 1 , further comprising using Compound A or a salt thereof to form sotorasib.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 9, 2025
From: SMITH, AUSTIN GERALD; KAVURU, PADMINI; DORNAN, PETER; DAI, XIJIE
To: AMGEN INC.
Reel/Frame 072198/0927 →
Continuity (3)
Continuation
18842194
Provisional Application
63317187
· Mar 7, 2022
References Cited (253)
US 5100883A
· Schiehser
· 1992
[cited by applicant]
US 5118677A
· Caufield
· 1992
[cited by applicant]
US 5118678A
· Kao et al.
· 1992
[cited by applicant]
US 5120842A
· Failli et al.
· 1992
[cited by applicant]
US 5151413A
· Caufield et al.
· 1992
[cited by applicant]
US 5256790A
· Nelson
· 1993
[cited by applicant]
US 5258389A
· Goulet et al.
· 1993
[cited by applicant]
US 5521184A
· Zimmermann
· 1996
[cited by applicant]
US 5650415A
· Tang et al.
· 1997
[cited by applicant]
US 5656643A
· Spada et al.
· 1997
[cited by applicant]
US 5712291A
· D'Amato
· 1998
[cited by applicant]
US 5728813A
· Lyman et al.
· 1998
[cited by applicant]
US 5747498A
· Schnur et al.
· 1998
[cited by applicant]
US 5770599A
· Gibson
· 1998
[cited by applicant]
US 5789427A
· Chen et al.
· 1998
[cited by applicant]
US 5792783A
· Tang et al.
· 1998
[cited by applicant]
US 5861510A
· Piscopio et al.
· 1999
[cited by applicant]
US 5863949A
· Robinson et al.
· 1999
[cited by applicant]
US 5892112A
· Levy et al.
· 1999
[cited by applicant]
US 5969110A
· Beckmann et al.
· 1999
[cited by applicant]
US 5981245A
· Fox et al.
· 1999
[cited by applicant]
US 5990141A
· Hirth et al.
· 1999
[cited by applicant]
US 6057124A
· Bartley et al.
· 2000
[cited by applicant]
US 6111090A
· Gorman et al.
· 2000
[cited by applicant]
US 6232447B1
· Cerretti
· 2001
[cited by applicant]
US 6235764B1
· Larson et al.
· 2001
[cited by applicant]
US 6258812B1
· Bold et al.
· 2001
[cited by applicant]
US 6413932B1
· Cerretti et al.
· 2002
[cited by applicant]
US 6515004B1
· Misra et al.
· 2003
[cited by applicant]
US 6596852B2
· Cerretti et al.
· 2003
[cited by applicant]
US 6630500B2
· Gingrich et al.
· 2003
[cited by applicant]
US 6656963B2
· Firestone et al.
· 2003
[cited by applicant]
US 6713485B2
· Carter et al.
· 2004
[cited by applicant]
US 6727225B2
· Wiley
· 2004
[cited by applicant]
US 7025962B1
· Gorman et al.
· 2006
[cited by applicant]
US 7618632B2
· Collins et al.
· 2009
[cited by applicant]
US 7812135B2
· Smith et al.
· 2010
[cited by applicant]
US 8388967B2
· Smith et al.
· 2013
[cited by applicant]
US 8586023B2
· Shiku et al.
· 2013
[cited by applicant]
US 8591886B2
· Ponath et al.
· 2013
[cited by applicant]
US 20030105091A1
· Riedl et al.
· 2003
[cited by applicant]
US 20090012085A1
· Baum et al.
· 2009
[cited by applicant]
US 20100022596A1
· Karl-Heinz
· 2010
[cited by applicant]
US 20200055845A1
· Lanman et al.
· 2020
[cited by applicant]
US 20220168280A1
· Lanman et al.
· 2022
[cited by applicant]
US 20220259150A1
· Wu et al.
· 2022
[cited by applicant]
CN 111205286A
· 2020
[cited by applicant]
CN 112479993A
· 2021
[cited by applicant]
DE 19629652A1
· 1998
[cited by applicant]
EP 0090505A2
· 1983
[cited by applicant]
EP 0407122A1
· 1991
[cited by applicant]
EP 0520722A1
· 1992
[cited by applicant]
EP 0566226A1
· 1993
[cited by applicant]
EP 0606046A1
· 1994
[cited by applicant]
EP 0682027A1
· 1995
[cited by applicant]
EP 0770622A2
· 1997
[cited by applicant]
EP 0780386A1
· 1997
[cited by applicant]
EP 0787772A2
· 1997
[cited by applicant]
EP 0818442A1
· 1998
[cited by applicant]
EP 0837063A1
· 1998
[cited by applicant]
EP 0931788A1
· 1999
[cited by applicant]
EP 1004578A1
· 2000
[cited by applicant]
EP 1181017A1
· 2002
[cited by applicant]
EP 0970070B1
· 2004
[cited by applicant]
EP 1786785A2
· 2007
[cited by applicant]
EP 1866339A2
· 2007
[cited by applicant]
EP 1947183A1
· 2008
[cited by applicant]
JP 02233610A
· 1990
[cited by applicant]
WO 9005719A1
· 1990
[cited by applicant]
WO 9205179A1
· 1992
[cited by applicant]
WO 9220642A1
· 1992
[cited by applicant]
WO 9311130A1
· 1993
[cited by applicant]
WO 9402136A1
· 1994
[cited by applicant]
WO 9402485A1
· 1994
[cited by applicant]
WO 9409010A1
· 1994
[cited by applicant]
WO 9509847A1
· 1995
[cited by applicant]
WO 9514023A1
· 1995
[cited by applicant]
WO 9516691A1
· 1995
[cited by applicant]
WO 9519774A1
· 1995
[cited by applicant]
WO 9519970A1
· 1995
[cited by applicant]
WO 9627583A1
· 1996
[cited by applicant]
WO 9630347A1
· 1996
[cited by applicant]
WO 9631510A1
· 1996
[cited by applicant]
WO 9633172A1
· 1996
[cited by applicant]
WO 9633980A1
· 1996
[cited by applicant]
WO 9641807A1
· 1996
[cited by applicant]
WO 9702266A1
· 1997
[cited by applicant]
WO 9713771A1
· 1997
[cited by applicant]
WO 9719065A1
· 1997
[cited by applicant]
WO 9727199A1
· 1997
[cited by applicant]
WO 9730034A1
· 1997
[cited by applicant]
WO 9730044A1
· 1997
[cited by applicant]
WO 9732880A1
· 1997
[cited by applicant]
WO 9732881A1
· 1997
[cited by applicant]
WO 9734895A1
· 1997
[cited by applicant]
WO 9738983A1
· 1997
[cited by applicant]
WO 9738994A1
· 1997
[cited by applicant]
WO 9749688A1
· 1997
[cited by applicant]
WO 9802434A1
· 1998
[cited by applicant]
WO 9802437A1
· 1998
[cited by applicant]
WO 9802438A1
· 1998
[cited by applicant]
WO 9802441A2
· 1998
[cited by applicant]
WO 9803516A1
· 1998
[cited by applicant]
WO 9807697A1
· 1998
[cited by applicant]
WO 9807726A1
· 1998
[cited by applicant]
WO 9814449A1
· 1998
[cited by applicant]
WO 9814450A1
· 1998
[cited by applicant]
WO 9814451A1
· 1998
[cited by applicant]
WO 9817662A1
· 1998
[cited by applicant]
WO 9830566A1
· 1998
[cited by applicant]
WO 9833768A1
· 1998
[cited by applicant]
WO 9833798A2
· 1998
[cited by applicant]
WO 9834915A1
· 1998
[cited by applicant]
WO 9834918A1
· 1998
[cited by applicant]
WO 9907675A1
· 1999
[cited by applicant]
WO 9907701A1
· 1999
[cited by applicant]
WO 9920758A1
· 1999
[cited by applicant]
WO 9929667A1
· 1999
[cited by applicant]
WO 9935132A1
· 1999
[cited by applicant]
WO 9935146A1
· 1999
[cited by applicant]
WO 9940196A1
· 1999
[cited by applicant]
WO 9945009A1
· 1999
[cited by applicant]
WO 9952889A1
· 1999
[cited by applicant]
WO 9952910A1
· 1999
[cited by applicant]
WO 9961422A1
· 1999
[cited by applicant]
WO 0002871A1
· 2000
[cited by applicant]
WO 0012089A1
· 2000
[cited by applicant]
WO 0059509A1
· 2000
[cited by applicant]
WO 0103720A2
· 2001
[cited by applicant]
WO 0114387A1
· 2001
[cited by applicant]
WO 0132651A1
· 2001
[cited by applicant]
WO 0137820A2
· 2001
[cited by applicant]
WO 0255501A2
· 2002
[cited by applicant]
WO 0259110A1
· 2002
[cited by applicant]
WO 0266470A1
· 2002
[cited by applicant]
WO 0268406A2
· 2002
[cited by applicant]
WO 2004005279A2
· 2004
[cited by applicant]
WO 2004007458A1
· 2004
[cited by applicant]
WO 2004007481A2
· 2004
[cited by applicant]
WO 2004009784A2
· 2004
[cited by applicant]
WO 2005005434A1
· 2005
[cited by applicant]
WO 2005007190A1
· 2005
[cited by applicant]
WO 2005011700A1
· 2005
[cited by applicant]
WO 2005016252A2
· 2005
[cited by applicant]
WO 2005055808A2
· 2005
[cited by applicant]
WO 2005115451A2
· 2005
[cited by applicant]
WO 2006044453A1
· 2006
[cited by applicant]
WO 2006083289A2
· 2006
[cited by applicant]
WO 2006121168A1
· 2006
[cited by applicant]
WO 2006122806A2
· 2006
[cited by applicant]
WO 2007133822A1
· 2007
[cited by applicant]
WO 2008070740A1
· 2008
[cited by applicant]
WO 2009036082A2
· 2009
[cited by applicant]
WO 2009055730A1
· 2009
[cited by applicant]
WO 2010003118A1
· 2010
[cited by applicant]
WO 2011028683
· 2011
[cited by applicant]
WO 2011051726A2
· 2011
[cited by applicant]
WO 2011090754A1
· 2011
[cited by applicant]
WO 2013039954A1
· 2013
[cited by applicant]
WO 2016118586A1
· 2016
[cited by applicant]
WO 2018119183A3
· 2018
[cited by applicant]
WO 2018217651A1
· 2018
[cited by applicant]
WO 2019051291A1
· 2019
[cited by applicant]
WO 2019213516A1
· 2019
[cited by applicant]
WO 2019213526A1
· 2019
[cited by applicant]
WO 2019217691A1
· 2019
[cited by applicant]
WO 2019232419A1
· 2019
[cited by applicant]
WO 2019241157A1
· 2019
[cited by applicant]
WO 2019243533A1
· 2019
[cited by applicant]
WO 2019243535A1
· 2019
[cited by applicant]
WO 2020050890A2
· 2020
[cited by applicant]
WO 2020102730A1
· 2020
[cited by applicant]
WO 2021047603A1
· 2021
[cited by applicant]
WO 2021097212A1
· 2021
[cited by applicant]
WO 2021097207A1
· 2021
[cited by applicant]
WO 2021123294A1
· 2021
[cited by applicant]
WO 2022076623A1
· 2022
[cited by applicant]
WO 2022109242A1
· 2022
[cited by applicant]
Dai et al., The Journal of Organic Chemistry, 2022, 87, pp. 8437-8444.
[cited by examiner]
Bagley et al., Rapid synthesis of 3-cyanopyridine-derived chromophores with two-dimensional tunability and solvatochromic photophysical properties, Chem. Commun. 5165-7 (2009).
[cited by applicant]
Canon, et al., “The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity,” Nature, 575(7781): 217-223 (2019) (Supplementary Material, pp. 1-55).
[cited by applicant]
Ciufolini et al., A Unified Strategy for the Synthesis of Phenanthroizidine Alkaloids: Preparation of Sterically Congested Pyrides, J. Am. Chem. Soc. 118:12082-9 (1996).
[cited by applicant]
Ciufolini et al., Modified Knoevenagel- Stobbe preparation of Substituted Pyridines: a New Approach to Streptonigrinoids, J. Chem. Soc. Chem. Commun., 1230 (1988).
[cited by applicant]
Dai et al., Synthesis of Substituted Pyridines via Formal (3+3) Cycloaddition of Enamines with Unsaturated Aldehydes and Ketones, J. Org. Chem., 87:8437-44 (2022).
[cited by applicant]
Database Registry [Online], Chemical Abstracts Service, Columbus, Ohio, US; Jul. 31, 2017 (Jul. 31, 2017), XP002801805, retrieved from STN Database accession No. 2105944-09-8.
[cited by applicant]
Hirai et al., Tailor-made synthesis of fully alkylated/arylatednicotinates by FeC13-mediated condensation of enamino esters with enones, Chem. Commun. 53:2390 (2017).
[cited by applicant]
International Search Report and Written Opinion, PCT/US2020/060415, dated Feb. 3, 2021.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2023/063755, dated May 25, 2023.
[cited by applicant]
Kato et al., Studies on Ketene and Its Derivatives LXXXI. Reaction of B-Amino crotonamide with a, B-Unsaturated Ketones, Chem. Parhm. Bull. 24:1408 (1976).
[cited by applicant]
Katritzky et al., A Simple and Versatile Route to Novel Conjugated â-Enaminonitriles and Their Application for the Highly Regioselective Synthesis of Nicotinonitriles Using a Vilsmeier-Type Reagent, J. Org. Chem., 64:60…
[cited by applicant]
Kong et al., Cascade Reactions Utilizing the Nucleophilic Properties of 1,1-Enediamines for the Regioselective Synthesis of 4-Aryl-2-aminopyridines, Chem. Select, 4:3083-7 (2019).
[cited by applicant]
Sarkar et al., Atom-Economical Palladium Carbon-Catalyzed de Novo Synthesis of Trisubstituted Nicotinonitriles, J. Org. Chem. 82:9012-22 (2017).
[cited by applicant]
Shibata et al., Syntheis of 4,6-Disubstituted 2-Methylpyridines and their 3-Carboxamides, J. Heterocyclic Chem. 30: 277 (1993).
[cited by applicant]
Shibata et al., “A Convenient Synthesis of 3-Cyano-2-methylpyridines under Ultrasonic Irradiation,” Bull. Chem. Soc. Jpn., 61:2199-2200 (1988).
[cited by applicant]
Song et al., One-Pot Reactions for Modular Synthesis of Polysubstituted and Fused Pyridines, Org. Lett. 18:5640-3 (2016).
[cited by applicant]
Stanetty et al., “Synthesis of Aza Analogs of the Herbicide Sindone B,” Monatshefte Fuer Chemie, 130:441-450 (1999).
[cited by applicant]
Taylor et al., Synthesis of D,L-7,10-Ethano-5-deazaaminopterin and L-7,10-Ethano-5-deazafolic Acid, J. Org. Chem., 50:1005-10 (1985).
[cited by applicant]
Wei et al., Modular Pyridine Synthesis from Oximes and Enals through Synergistic Copper/Iminium Catalysis, J. Org. Chem. 135:3756-9 (2013).
[cited by applicant]
4-methyl-2-(1-methylethyl)-3-Pyridinamine, STN Registry, CAS RN 1698293-93-4, STN entry date May 5, 2015 (May 5, 2015).
[cited by applicant]
“GTPase KRas isoform a [
[cited by applicant]
ATTC “Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma),” Accession No. HB-8508, retrieved from https://www.atcc.org/˜/media/0DF7351153724BD6A3E7D78D5BA2F933.ashx, on Nov. 29, 2018.
[cited by applicant]
Barnett et al., “Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors,” Biochem J., 385:399-408 (2005).
[cited by applicant]
Biernacka et al. “The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma” in
[cited by applicant]
Carlone et al., “A simple asymmetric organocatalytic approach to optically active cyclohexenones”, Chemical Communications, 47:4928-4930 (2006).
[cited by applicant]
Clarke et al. “Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer” in Oncogene, 38:5076-90 (2019).
[cited by applicant]
Cox et al., “Drugging the undruggable RAS: mission possible?” in
[cited by applicant]
Dasmahapatra et al., “In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell Lines,” Clin. Cancer Res., 10(15): 5242-52 (2…
[cited by applicant]
Del Re et al. “Implications of KRAS mutations in acquired resistance to treatment in NSCLC” in Oncotarget., 9:6630-43 (2017).
[cited by applicant]
Fiala et al. “G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab” in
[cited by applicant]
Giils et al., “The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt,” Expert. Opin. Investig. Drugs, 13:787-797. (2004).
[cited by applicant]
Goldberg et al., “Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells,” Blood, The Journal of the American Society of Hematology, 110(1):186-192 (2007).
[cited by applicant]
Goldstein et al., “Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.,” Clin. Cancer Res., 1:1311-1318 (1995).
[cited by applicant]
Huang et al., “Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck, ” Cancer Res, 59(8):1935-1940 (1999).
[cited by applicant]
Jin et al., “Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells, ” Br. J Cancer, 91, 1808-1812 (2004).
[cited by applicant]
Jones et al. “Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer,”
[cited by applicant]
Kargbo Rb. “Inhibitors of G12C mutant Ras proteins for the treatment of cancers”,
[cited by applicant]
Lievre, “KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer”
[cited by applicant]
Lito et al., “Allele-specific inhibitors inactivate mutant Kras G12C by a trapping mechanism”
[cited by applicant]
Massarelli et al. “KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer”
[cited by applicant]
McCormick F. “K-Ras protein as a drug target”
[cited by applicant]
Modjtahedi et al., “The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468,” British journal of cancer, 67(2):247-253 (1993).
[cited by applicant]
Nadai et al. “KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma”
[cited by applicant]
Neumann et al., “Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer”
[cited by applicant]
Ostrem et al., “K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions”
[cited by applicant]
Ostrem et al., “Direct small molecule inhibitors of KRAS: from structural insights to mechanism-based design”
[cited by applicant]
Ouerhani et al., “The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer”
[cited by applicant]
Paez et al., “EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy,” Science, 304, Issue 5676, 1497-500 (2004).
[cited by applicant]
Parsons, et al., Axial Chirality in the Sotorasib Drug Substance, Part 1: Development of a Classical Resolution to Prepare an Atropisomerically Pure Sotorasib Intermediate,
[cited by applicant]
Patricelli et al. “Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state” in
[cited by applicant]
Remington's Pharmaceutical Sciences, 18th Edition, A.R. Gennaro, Chapter 75:1435-1712 (1990) (280 pages).
[cited by applicant]
Sarkar et al., “Indole-3-carbinol and prostate cancer,” J. Nutr., 134:3493S-3498S. (2004).
[cited by applicant]
Simanshu et al., “RAS proteins and their regulators in human disease”
[cited by applicant]
Suzawa et al. “Activation of KRAS mediates resistance to targeted therapy in MET exon 14-mutant non-small cell lung cancer” in
[cited by applicant]
Teramoto et al., “Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer,” Cancer, 77, 639-645 (1996).
[cited by applicant]
Thompson et al., “PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma, ” Clin. Cancer Res., 13(6): 1757-1761 (2007).
[cited by applicant]
Traxler P., “Tyrosine kinase inhibitors in cancer treatment (part II),” Exp. Opin. Ther. Patents, 8(12):1599-1625. (1998).
[cited by applicant]
Verghese et al., “Increasing global access to the high-vol. HIV drug nevirapine through process intensification.”
[cited by applicant]
Wei et al., “Modular Pyridine Synthesis from Oximes and Enals through Synergistic Copper/Iminium Catalysis,” JAS. 135:3756-9 (2013).
[cited by applicant]
Yan et al., “Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development,” Biotechniques, 39(4):565-568 (2005).
[cited by applicant]
Yang et al., “Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt,” Cancer Res., 64:4394-4399 (2004).
[cited by applicant]
Yang et al., “Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy,” Cancer Res., 59:1236-1243. (1999).
[cited by applicant]
Notice of Allowance, mailed Oct. 3, 2023, for U.S. Appl. No. 17/031,607, 7 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/031,607, mailed Mar. 31, 2023, 7 pages.
[cited by applicant]
Restriction Requirement, mailed Apr. 14, 2022, for U.S. Appl. No. 17/031,607, 5 pages.
[cited by applicant]
Cited By (2)